Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival

Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis

(2022) Matthew G. Davey et al.   BJS Open

Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study

(2021) Joyce O’Shaughnessy et al.   BREAST CANCER RESEARCH AND TREATMENT

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

(2021) Larissa A. Korde et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

(2021) Martine Piccart et al.   JOURNAL OF CLINICAL ONCOLOGY

Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer

(2021) Anna van der Voort et al.   JAMA Oncology

The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data

(2021) Andreia Borges et al.   Health Economics Review

Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)

(2020) Santiago González-Santiago et al.   BREAST CANCER RESEARCH AND TREATMENT

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2019) Sara M. Tolaney et al.   JOURNAL OF CLINICAL ONCOLOGY

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2019) F Cardoso et al.   ANNALS OF ONCOLOGY

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

(2019) Sara A. Hurvitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence and management of diarrhea with adjuvant pertuzumab and trastuzumab in HER2-positive breast cancer patients

(2019) Bines J et al.   Clinical Breast Cancer

Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer

(2018) Andreas Schneeweiss et al.   EUROPEAN JOURNAL OF CANCER

Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis

(2018) Peter A. Fasching et al.   BREAST CANCER RESEARCH AND TREATMENT

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

(2018) Mette S van Ramshorst et al.   LANCET ONCOLOGY

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

(2017) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

(2016) Luca Gianni et al.   LANCET ONCOLOGY

Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes

(2016) Kristine R. Broglio et al.   JAMA Oncology

Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer

(2014) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

(2013) A. Schneeweiss et al.   ANNALS OF ONCOLOGY

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY